INM RSI Chart
Last 7 days
-17.9%
Last 30 days
-36.1%
Last 90 days
-36.1%
Trailing 12 Months
-80.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 2.3M | 4.1M | 4.7M | 5.5M |
2022 | 0 | 1.1M | 1.4M | 1.6M |
2021 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 21, 2024 | hull andrew | bought | 14,625 | 0.39 | 37,500 | - |
Feb 20, 2024 | adams eric a | bought | 14,921 | 0.3587 | 41,600 | president & ceo |
Apr 14, 2022 | adams eric a | bought | 12,659 | 0.894 | 14,160 | president & ceo |
Apr 13, 2022 | adams eric a | bought | 7,276 | 0.85 | 8,560 | president & ceo |
Jan 24, 2022 | colwill bruce | bought | 5,438 | 1.0877 | 5,000 | cfo |
Jan 06, 2022 | johnson shane aaron | bought | 10,710 | 1.26 | 8,500 | svp, gm of baymedica llc |
Dec 30, 2021 | johnson shane aaron | bought | 10,736 | 1.3266 | 8,093 | svp, gm of baymedica llc |
Nov 15, 2021 | johnson shane aaron | bought | 6,845 | 1.369 | 5,000 | svp, gm of baymedica llc |
Sep 29, 2021 | adams eric a | bought | 15,224 | 1.73 | 8,800 | president & ceo |
Sep 28, 2021 | colwill bruce | bought | 8,840 | 1.768 | 5,000 | cfo |
Which funds bought or sold INM recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 23, 2024 | Global Retirement Partners, LLC | unchanged | - | - | 2.00 | -% |
Apr 23, 2024 | BFSG, LLC | new | - | 73.00 | 73.00 | -% |
Apr 12, 2024 | AdvisorNet Financial, Inc | new | - | 29.00 | 29.00 | -% |
Feb 14, 2024 | BANK OF AMERICA CORP /DE/ | new | - | 42.00 | 42.00 | -% |
Feb 14, 2024 | AllSquare Wealth Management LLC | unchanged | - | -5.00 | 9.00 | -% |
Feb 14, 2024 | SABBY MANAGEMENT, LLC | new | - | 212,965,000 | 212,965,000 | 0.21% |
Feb 14, 2024 | TWO SIGMA SECURITIES, LLC | new | - | 5,364 | 5,364 | -% |
Feb 14, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | sold off | -100 | -18,346 | - | -% |
Feb 14, 2024 | Royal Bank of Canada | reduced | -57.69 | - | - | -% |
Feb 14, 2024 | CITADEL ADVISORS LLC | new | - | 14,148 | 14,148 | -% |
Unveiling InMed Pharmaceuticals Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to InMed Pharmaceuticals Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.1B | 6.8B | -8.94 | 6.15 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.1B | 1.8B | -41.18 | 9.92 | ||||
BMRN | 15.3B | 2.5B | 74.64 | 6.2 | ||||
INCY | 11.7B | 3.7B | 19.56 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.3B | 396.6M | -10.08 | 13.43 | ||||
BBIO | 4.5B | - | -6.9 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.61 | 12.91 | ||||
ARWR | 2.8B | 240.7M | -9.44 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -44.93 | 3.79 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 24.84 | 4.45 | ||||
NVAX | 606.0M | 983.7M | -1.11 | 0.62 | ||||
CRBP | 388.7M | 881.7K | -8.71 | 466.16 | ||||
INO | 267.6M | 4.9M | -1.98 | 54.99 | ||||
IBIO | 6.0M | 2.1M | -0.22 | 2.14 |
InMed Pharmaceuticals Inc. News
Income Statement (Quarterly) | ||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 37.5% | 1,240,200 | 901,862 | 2,311,065 | 1,033,925 | 469,783 | 320,788 | 525,323 | 309,585 | 265,092 |
Cost Of Revenue | - | - | - | 1,008,520 | 841,414 | 338,620 | 235,034 | - | 127,308 | 153,537 |
Gross Profit | 1425.9% | 324,142 | 21,242 | 1,570,380 | 192,511 | 131,163 | -491,018 | - | 182,277 | 111,555 |
Operating Expenses | -26.9% | 1,969,087 | 2,694,113 | 2,048,365 | 2,341,719 | 2,345,047 | 3,084,969 | 6,769,689 | 3,721,902 | 4,423,653 |
S&GA Expenses | 5.0% | 1,363,958 | 1,298,731 | 1,409,435 | 1,412,727 | 1,464,879 | 1,560,477 | 1,742,360 | 1,915,017 | 1,836,786 |
R&D Expenses | -52.8% | 609,791 | 1,292,093 | 623,744 | 878,303 | 851,356 | 1,378,653 | 1,500,748 | 1,753,545 | 2,537,070 |
EBITDA Margin | 22.0% | -1.12 | -1.43 | -1.96 | -6.65 | -10.52 | -13.57 | -17.23 | - | - |
Interest Expenses | - | - | - | - | -1,500 | -3,000 | -6,800 | - | - | - |
Income Taxes | - | - | - | - | - | 3,000 | 6,800 | - | - | - |
Earnings Before Taxes | 41.7% | -1,478,185 | -2,536,828 | -336,591 | -1,996,444 | -2,098,087 | -3,503,400 | -7,870,023 | -3,475,665 | -4,282,814 |
EBT Margin | 21.7% | -1.16 | -1.48 | -1.92 | -6.58 | -10.43 | -13.47 | -17.07 | - | - |
Net Income | 41.7% | -1,478,185 | -2,536,828 | -338,391 | -1,997,944 | -2,101,087 | -3,510,200 | -7,870,023 | -3,475,665 | -4,282,814 |
Net Income Margin | 21.7% | -1.16 | -1.48 | -1.92 | -6.59 | -10.43 | -13.47 | -17.07 | - | - |
Free Cashflow | 100.0% | - | -2,174,213 | -657,934 | -1,656,626 | -2,713,096 | -2,255,543 | -4,047,247 | -5,352,339 | -3,319,363 |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Assets | 39.7% | 15,255 | 10,917 | 14,106 | 14,730 | 16,920 | 14,584 | 12,788 | 15,486 | 19,384 | 17,327 | 9,781 | 12,345 | 11,747 | 6,604 | 7,803 |
Current Assets | 42.4% | 11,810 | 8,295 | 11,332 | 11,843 | 14,018 | 11,543 | 9,598 | 8,747 | 12,505 | 15,976 | 8,378 | 10,897 | 10,249 | 5,117 | 6,312 |
Cash Equivalents | 41.5% | 9,535 | 6,738 | 8,913 | 9,604 | 11,453 | 9,350 | 6,177 | 5,898 | 11,280 | 15,344 | 7,363 | 9,454 | 10,021 | 4,497 | 5,806 |
Inventory | -34.3% | 745 | 1,133 | 1,616 | 1,330 | 1,614 | 1,779 | 2,491 | 1,420 | 989 | - | - | - | - | - | - |
Net PPE | 140.8% | 1,481 | 615 | 723 | 753 | 704 | 802 | 904 | 1,003 | 1,097 | 305 | 327 | 348 | 374 | 385 | 403 |
Goodwill | - | - | - | - | - | - | - | - | 2,023 | 2,023 | - | - | - | - | - | - |
Liabilities | 85.4% | 2,483 | 1,339 | 2,017 | 2,342 | 2,585 | 3,576 | 3,709 | 4,599 | 5,216 | 2,106 | 2,405 | 1,931 | 4,157 | 2,110 | 1,924 |
Current Liabilities | 25.5% | 1,680 | 1,339 | 2,001 | 2,270 | 2,401 | 3,282 | 3,320 | 4,106 | 4,618 | 1,927 | 2,215 | 1,714 | 2,154 | 1,874 | 1,676 |
Short Term Borrowings | - | - | - | - | - | - | - | - | 29.00 | 59.00 | - | - | - | - | - | - |
Shareholder's Equity | 33.3% | 12,772 | 9,578 | 12,090 | 12,388 | 14,335 | 11,008 | 9,079 | 10,887 | 14,167 | 15,222 | 7,377 | 10,414 | 7,591 | 4,494 | 5,878 |
Retained Earnings | -1.4% | -105,400 | -103,900 | -101,400 | -101,061 | -99,063 | -96,962 | -93,452 | -85,582 | -82,106 | -77,824 | -74,852 | -71,593 | -68,492 | -66,248 | -64,649 |
Additional Paid-In Capital | 6.6% | 38,122 | 35,766 | 35,741 | 35,701 | 38,408 | 35,171 | 31,684 | 26,515 | 27,049 | 29,230 | 21,513 | 21,292 | 17,946 | 17,850 | 17,764 |
Shares Outstanding | 70.3% | 5,668 | 3,328 | 3,328 | 3,328 | 1,583 | 866 | 651 | 533 | 554 | 482 | 322 | 322 | 280 | - | - |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 |
Cashflow From Operations | 15.0% | -1,848 | -2,174 | -657 | -1,656 | -2,713 | -2,255 | -4,047 | -5,348 | -3,533 | -2,653 | -2,006 | -4,611 | -1,801 | -1,371 | -1,398 | -1,521 | -2,089 | -2,365 |
Share Based Compensation | -27.5% | 18.00 | 25.00 | - | 50.00 | 71.00 | 117 | 177 | 195 | 215 | 111 | 221 | 207 | 97.00 | 85.00 | 156 | 204 | 284 | 350 |
Cashflow From Investing | - | - | - | -33.61 | -128 | - | - | -725 | -3.55 | 306 | -250 | - | - | - | - | 918* | -8.80 | 55.00 | 3,744 |
Cashflow From Financing | - | - | - | - | -63.70 | 5,315 | 5,429 | 5,051 | -29.31 | -836 | 10,885 | -83.18 | 4,045 | 6,958 | -64.65 | - | - | - | - |
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||||
Sales | $ 1,240,200 | $ 469,783 | $ 2,142,062 | $ 790,571 |
Cost of sales | 745,584 | 338,620 | 1,533,274 | 573,654 |
Inventory write-down | 170,474 | 263,404 | 576,772 | |
Gross profit | 324,142 | 131,163 | 345,384 | (359,855) |
Operating Expenses | ||||
Research and development and patents | 609,791 | 851,356 | 1,901,884 | 2,230,009 |
General and administrative | 1,363,958 | 1,464,879 | 2,662,689 | 3,025,356 |
Amortization and depreciation | 55,234 | 49,049 | 110,066 | 98,097 |
Foreign exchange (gain) loss | (59,896) | (20,237) | (11,439) | 76,554 |
Total operating expenses | 1,969,087 | 2,345,047 | 4,663,200 | 5,430,016 |
Other Income (Expense) | ||||
Interest and other income | 166,760 | 115,797 | 302,803 | 188,384 |
Loss before income taxes | (1,478,185) | (2,098,087) | (4,015,013) | (5,601,487) |
Tax expense | (3,000) | (9,800) | ||
Net loss for the period | $ (1,478,185) | $ (2,101,087) | $ (4,015,013) | $ (5,611,287) |
Net loss per share for the period | ||||
Basic (in Dollars per share) | $ (0.19) | $ (0.91) | $ (0.71) | $ (3.54) |
Weighted average outstanding common shares | ||||
Basic (in Shares) | 7,973,465 | 2,300,526 | 5,650,828 | 1,583,073 |
Condensed Consolidated Interim Balance Sheets - USD ($) | Dec. 31, 2023 | Jun. 30, 2023 |
---|---|---|
Current | ||
Cash and cash equivalents | $ 9,534,922 | $ 8,912,517 |
Short-term investments | 44,462 | 44,422 |
Accounts receivable, net | 372,870 | 260,399 |
Inventories | 744,839 | 1,616,356 |
Prepaids and other current assets | 1,112,977 | 498,033 |
Total current assets | 11,810,070 | 11,331,727 |
Non-Current | ||
Property, equipment and ROU assets, net | 1,481,102 | 723,426 |
Intangible assets, net | 1,864,292 | 1,946,279 |
Other assets | 100,000 | 104,908 |
Total Assets | 15,255,464 | 14,106,340 |
Current | ||
Accounts payable and accrued liabilities | 1,287,623 | 1,608,735 |
Current portion of lease obligations | 364,190 | 375,713 |
Deferred rent | 28,656 | 16,171 |
Total current liabilities | 1,680,469 | 2,000,619 |
Non-current | ||
Lease obligations, net of current portion | 802,784 | 15,994 |
Total Liabilities | 2,483,253 | 2,016,613 |
Commitments and Contingencies | ||
Common shares, no par value, unlimited authorized shares, 3,328,191 (June 30, 2023 - 3,328,191) issued and outstanding | 79,936,633 | 77,620,252 |
Additional paid-in capital | 38,122,231 | 35,741,115 |
Accumulated deficit | (105,415,222) | (101,400,209) |
Accumulated other comprehensive income | 128,569 | 128,569 |
Total Shareholders’ Equity | 12,772,211 | 12,089,727 |
Total Liabilities and Shareholders’ Equity | $ 15,255,464 | $ 14,106,340 |